Literature DB >> 22464044

Deposition of inhaled particles in the lungs.

Ana Fernández Tena1, Pere Casan Clarà.   

Abstract

Inhaled medication is the first-line treatment of diseases such as asthma or chronic obstructive pulmonary disease. Its effectiveness is related to the amount of drug deposited beyond the oropharyngeal region, the place where the deposit occurs and its distribution (uniform or not). It is also important to consider the size of the inhaled particles, the breathing conditions, the geometry of the airways and the mucociliary clearance mechanisms. Currently, mathematical models are being applied to describe the deposition of inhaled drugs based on the size of the particles, the inspiratory flow and the anatomical distribution of the bronchial tree. The deposition of particles in the small airways gets maximum attention from pharmaceutical companies and is of great interest as it is related with a better control in patients receiving these drugs.
Copyright © 2012 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22464044     DOI: 10.1016/j.arbres.2012.02.003

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  30 in total

Review 1.  Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.

Authors:  Cheng Loong Ngan; Azren Aida Asmawi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

2.  Nuclear medicine: workplace monitoring and internal occupational exposure during a ventilation/perfusion single-photon emission tomography.

Authors:  J Martínez; T Baciu; M Artigues; M Danús; A Peñalver; C Aguilar; F Borrull
Journal:  Radiat Environ Biophys       Date:  2019-05-28       Impact factor: 1.925

3.  Exosome-Mediated Small RNA Delivery: A Novel Therapeutic Approach for Inflammatory Lung Responses.

Authors:  Duo Zhang; Heedoo Lee; Xiaoyun Wang; Ashish Rai; Michael Groot; Yang Jin
Journal:  Mol Ther       Date:  2018-07-10       Impact factor: 11.454

Review 4.  Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension.

Authors:  Ali Keshavarz; Hossam Kadry; Ahmed Alobaida; Fakhrul Ahsan
Journal:  Expert Opin Drug Deliv       Date:  2020-02-19       Impact factor: 6.648

Review 5.  Integrating Lung Physiology, Immunology, and Tuberculosis.

Authors:  Jordi B Torrelles; Larry S Schlesinger
Journal:  Trends Microbiol       Date:  2017-03-30       Impact factor: 17.079

6.  Enhanced reseeding of decellularized rodent lungs with mouse embryonic stem cells.

Authors:  Shimon Lecht; Collin T Stabler; Alexis L Rylander; Rachel Chiaverelli; Edward S Schulman; Cezary Marcinkiewicz; Peter I Lelkes
Journal:  Biomaterials       Date:  2014-01-15       Impact factor: 12.479

7.  Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model.

Authors:  James Verco; William Johnston; Michael Baltezor; Philip J Kuehl; Andrew Gigliotti; Steven A Belinsky; Anita Lopez; Ronald Wolff; Lauren Hylle; Gere diZerega
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-25       Impact factor: 2.849

8.  Polymeric nanoparticles for pulmonary protein and DNA delivery.

Authors:  Jyothi U Menon; Priya Ravikumar; Amruta Pise; Dipendra Gyawali; Connie C W Hsia; Kytai T Nguyen
Journal:  Acta Biomater       Date:  2014-02-08       Impact factor: 8.947

9.  Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.

Authors:  Alanood S Almurshedi; Basmah N Aldosari; Hessah A Aljunaidel; Bushra Alquadeib; Iman M Alfagih; Salma S Almarshidy; Eram K D Eltahir; Amany Z Mohamoud
Journal:  Int J Nanomedicine       Date:  2021-03-25

10.  SARS CoV-2 aerosol: How far it can travel to the lower airways?

Authors:  Mohammad S Islam; Puchanee Larpruenrudee; Akshoy Ranjan Paul; Gunther Paul; Tevfik Gemci; Yuantong Gu; Suvash C Saha
Journal:  Phys Fluids (1994)       Date:  2021-06-03       Impact factor: 3.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.